New Option Soon for Some European Patients With Leukemia
Gilteritinib has been recommended for approval for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation.
Related Articles
Home
Sunday, 15 September, 2024 | 13:00 – 14:30 CEST BURGOS AUDITORIUM, HALL 5, FIRA BARCELONA GRAN VIA, BARCELONA, SPAIN Supported by an independent educational grant…
Home
Sunday, 15 September, 2024 | 13:00 – 14:30 CEST BURGOS AUDITORIUM, HALL 5, FIRA BARCELONA GRAN VIA, BARCELONA, SPAIN Supported by an independent educational grant…
Home
Monday, 16 September, 2024 | 18:30 – 20:00 CEST VALENCIA AUDITORIUM, HALL 5, FIRA BARCELONA GRAN VIA, BARCELONA, SPAIN Supported by an independent educational grant…
Home
Monday, 16 September, 2024 | 18:30 – 20:00 CEST VALENCIA AUDITORIUM, HALL 5, FIRA BARCELONA GRAN VIA, BARCELONA, SPAIN Supported by an independent educational grant…
Home
Friday, December 6, 2024 3:30 pm – 5:00 pm PT Room: Grand Ballroom 8-9 Marriott Marquis SD | San Diego, California CME/CNE/CPE Hybrid Join a…
Home
Sunday, 15 September, 2024 | 13:00 – 14:30 CEST BURGOS AUDITORIUM, HALL 5, FIRA BARCELONA GRAN VIA, BARCELONA, SPAIN Supported by an independent educational grant…
Home
Monday, 16 September, 2024 | 18:30 – 20:00 CEST VALENCIA AUDITORIUM, HALL 5, FIRA BARCELONA GRAN VIA, BARCELONA, SPAIN Supported by an independent educational grant…
Home
Monday, 16 September, 2024 | 18:30 – 20:00 CEST VALENCIA AUDITORIUM, HALL 5, FIRA BARCELONA GRAN VIA, BARCELONA, SPAIN Supported by an independent educational grant…
MDT Care in Endometrial Cancer: Responsibilities of the Care Team
Join Medscape Oncology for a live interactive social media event on themultidisciplinary care for patients with endometrial cancer. Our multidisciplinarypane…